To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.19, delivering a surprise of -11.76%.Over the last four quarters, the company has surpa ...

TELA Bio (NasdaqGM:TELA) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsCaitlin Roberts - Director of MedTech Equity ResearchJeff Blizard - PresidentJim Hagen - SVP of CommercialLouisa Smith - Investor RelationsRoberto Cuca - COO and CFOTony Koblish - Co Founder and CEOConference Call ParticipantsFrank Takkinen - Senior Research AnalystMatthew O'Brien - Senior Research AnalystMichael Sarcone - Equity Research AnalystOperatorGood afternoon, ladies and gentlemen, and welcome to the TELA ...

TELA Bio (NasdaqGM:TELA) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsCaitlin Roberts - Director of MedTech Equity ResearchJeff Blizard - PresidentJim Hagen - SVP of CommercialLouisa Smith - Investor RelationsRoberto Cuca - COO and CFOTony Koblish - Co Founder and CEOConference Call ParticipantsFrank Takkinen - Senior Research AnalystMatthew O'Brien - Senior Research AnalystMichael Sarcone - Equity Research AnalystOperatorGood afternoon, ladies and gentlemen, and welcome to the TELA ...

TELA Bio (NasdaqGM:TELA) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Speaker8Good afternoon, ladies and gentlemen, and welcome to the TELA Bio fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the prepared remarks. As a reminder, this conference call is being recorded. I would now like to turn the conference call over to Louisa Smith from Investor Relations.Speaker5Thank you, Jonathan, and good a ...

Exhibit 99.1 Recent Highlights "We closed 2025 with our strongest quarterly revenue on record, delivering $20.9 million and 18% growth over Q4 2024 while holding operating expenses essentially flat for the year, demonstrating the operating leverage we expect to continue to see in the years ahead," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "Over the last six months we strengthened our leadership and upgraded the commercial field organization. Today, the team we have assembled i ...

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024;Expanded the sales force to ...

Core Viewpoint - TELA Bio, Inc. will report its fourth quarter and full year 2025 financial results on March 24, 2026, and will host a conference call and webcast to discuss these results and provide a corporate update [1]. Group 1: Financial Reporting - The financial results for the fourth quarter and full year 2025 will be announced on March 24, 2026 [1]. - A conference call and webcast will take place at 4:30 p.m. ET on the same day to discuss the financial results [1]. Group 2: Conference Call Details - Investors interested in the conference call must register online at least 15 minutes before the start [2]. - A live webcast and replay will be available on the Events & Presentations page of TELA's investor section [2]. Group 3: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [3]. - The company aims to optimize clinical outcomes by preserving and restoring the patient's anatomy while minimizing long-term exposure to synthetic materials [3].

Core Viewpoint - TELA Bio, Inc. has approved inducement grants of restricted stock units to five newly-hired employees as part of their employment compensation, aimed at enhancing talent acquisition and retention [1]. Group 1: Inducement Grants - The Compensation Committee of TELA Bio's Board of Directors approved grants covering 14,250 shares of common stock to five new employees, with a grant date of January 20, 2026 [1]. - The restricted stock units will vest in equal annual installments over four years, contingent on the employees' continued service with TELA Bio [2]. Group 2: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's own anatomy [3]. - The company aims to provide advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials [3].

TELA Bio FY Conference Summary Company Overview - **Company**: TELA Bio (NasdaqGM: TELA) - **Industry**: Medical Technology, specifically focused on hernia repair and plastic reconstruction Key Points and Arguments Product Strength and Market Position - TELA Bio claims to have the best hernia product on the market, combining the strength of synthetic materials with the benefits of biologics [6][8] - The company is currently in the early adopter phase of market penetration, with aspirations to reach the mainstream market [15] - TELA Bio's revenue has grown from approximately $10-$12 million at the start of 2020 to an $80 million business focused on hernia repair and breast reconstruction [16][17] Competitive Landscape - TELA Bio's product portfolio is compared to established competitors like Becton, Dickinson's Bard portfolio and LifeCell, with Bard's hernia business estimated at around $600 million and LifeCell at approximately $500 million [17][18] - The company aims to capture market share from competitors by focusing on natural repair products, which are gaining traction among younger surgeons [24][25] Sales and Marketing Strategy - TELA Bio has recently upgraded its commercial leadership team and board to enhance sales force effectiveness and operational execution [19] - The company has identified gaps in its sales regions and is actively working to fill these with new talent [20] - The sales force currently consists of 76 representatives, with plans to expand to 90 by the end of Q1 2026 [88][89] Financial Performance and Projections - TELA Bio has set a revenue growth target of at least 15% for the next year, with potential for upside based on new product launches and earlier hiring of sales reps [82][92] - The company ended Q3 with approximately $30 million in cash and has access to additional funds through a debt facility, positioning it well to avoid further fundraising in the near term [126] Product Development and Innovation - TELA Bio plans to double its hernia portfolio in the first half of 2026, introducing a new long-term resorbable polymer product [36][37] - The company is also developing two new plastic and reconstructive products aimed at expanding its market opportunities [98][99] Operational Efficiency - The company has reduced its sales and marketing spend from 93% of sales to 70-73%, indicating improved operational efficiency [29] - TELA Bio aims to manage volatility better as it scales from $80 million to $200 million in revenue [27][28] Challenges and Risks - The company faces institutional inertia in the healthcare system, where established surgeons may be resistant to adopting new products [27] - TELA Bio acknowledges the need to improve execution and manage the transition from a startup phase to a more established business model [25][28] Additional Important Insights - TELA Bio's pricing strategy positions its products between traditional polypropylene mesh and first-generation biologics, aiming to maintain ASPs while offering economic value [35][36] - The company has a strong focus on clinical data to support its product offerings, which is crucial for gaining surgeon and patient trust [41][46] This summary encapsulates the key insights from TELA Bio's FY conference, highlighting the company's strategic positioning, growth trajectory, and operational plans within the medical technology industry.